Testing a New Treatment for Geographic Atrophy
Part of Eyes & vision clinical trials.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 60 or older
- Diagnosed with age-related macular degeneration (AMD) with geographic atrophy in at least one eye
- Geographic atrophy area between 2.5 and 10.16 mm² (measured by special eye imaging)
- Vision in the study eye at least 20/70 (correctable with glasses)
- Able to receive vaccinations against meningitis and pneumonia before starting treatment
- Willing to take daily medication and attend regular eye exams
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This trial tests an investigational treatment called PST-611 for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. It aims to see if the treatment is safe and may slow the progression of the disease.
This study tests a new gene therapy that may slow or stop the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as an injection into the eye and aims to preserve remaining vision.
This study uses special eye imaging to look closely at areas of damage in the back of the eye (geographic atrophy) caused by age-related macular degeneration. It will help doctors understand early-stage disease better and may guide future treatments.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.